Drugs & Therapy Perspectives

, Volume 29, Issue 6, pp 155–160

Pegloticase: a guide to its use in treatment-refractory chronic gout in the EU

Adis Drug Clinical Q&A

DOI: 10.1007/s40267-013-0039-7

Cite this article as:
Lyseng-Williamson, K.A. Drugs Ther Perspect (2013) 29: 155. doi:10.1007/s40267-013-0039-7
  • 66 Downloads

Abstract

Intravenous pegloticase (KRYSTEXXA®), a recombinant polyethylene glycol-conjugated form of uricase (a uric acid-specific enzyme lacking in humans), is a novel approach to treating chronic gout refractory to conventional therapy. Pegloticase 8 mg every 2 weeks provides sustained reductions in plasma uric acid levels to less than the therapeutic target of 6 mg/dL (360 μmol/L) in a substantial proportion of patients with chronic refractory gout. The risk of infusion-related reactions can be minimized by following the recommended precautions, which include monitoring of serum uric acid levels.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisNorth ShoreNew Zealand